CRISPR/Cas9-mediated gene deletion efficiently retards the progression of Philadelphia-positive acute lymphoblastic leukemia in a p210 BCR-ABL1T315I mutation mouse model
Yu-Ting Tan,
Lin Ye,
Fei Xie,
Jiaming Wang,
Markus Müschen,
Sai-Juan Chen,
Yuet Wai Kan,
Han Liu
Affiliations
Yu-Ting Tan
State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Rui Jin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China;Department of Medicine, University of California San Francisco, San Francisco, CA, USA
Lin Ye
Department of Medicine, University of California San Francisco, San Francisco, CA, USA
Fei Xie
Department of Medicine, University of California San Francisco, San Francisco, CA, USA;Present address: Eureka Therapeutics, Emeryville, CA, USA
Jiaming Wang
Department of Medicine, University of California San Francisco, San Francisco, CA, USA
Markus Müschen
Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA;Department of Systems Biology, City of Hope Comprehensive Cancer Center, Monrovia, CA, USA
Sai-Juan Chen
State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Rui Jin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
Yuet Wai Kan
Department of Medicine, University of California San Francisco, San Francisco, CA, USA;Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA;Institute for Human Genetics, University of California San Francisco, San Francisco, CA, USA
Han Liu
State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Rui Jin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
